RISK & WARNING DISCLAIMER

The Medtech Syndicate does not offer, nor will offer, any financial services or investment guidance to any individual or entity. Our role does not include promoting, endorsing, or selling investment opportunities. Instead, we introduce start-up companies to our members. Should a member decide to proceed with an investment, our involvement is limited to assisting in the execution of the investment process.

The Medtech Syndicate, along with the potential investment opportunities it presents, is not overseen by any Financial Regulatory Authority. Consequently, any investments made through the Syndicate do not benefit from protections such as deposit guarantee schemes or investor compensation schemes. Individuals contemplating an investment are advised to conduct their own comprehensive evaluation regarding the legal, tax, financial, and additional implications of an investment, including the potential benefits and associated risks.

Those considering an investment should not regard any content on this presentation, related websites, or any materials provided by us as legal, tax, or investment advice, nor should it be seen as an invitation to invest. It is recommended that potential investors seek guidance from their own professional advisors for independent advice on financial, investment, tax, and legal matters.

Investing in startups carries significant risks, such as the complete loss of investment, lack of liquidity, share dilution, and the absence of dividends, and is only appropriate for investors who have the capacity to understand and take on these risks.

THE MEDTECH SYNDICATE

We are an Irish-based syndicate of passionate investors dedicated to fostering innovation within the Medical Technology ecosystem. Founded in 2014 by seasoned entrepreneurs and former leaders from renowned medtech companies such as Medtronic, Boston Scientific, Abbott, and Creganna, our group brings together a wealth of experience and industry insight.

Our members possess diverse expertise spanning life sciences, technology, and financial services. While many of our investors are based in Ireland, our network is growing internationally, enabling us to build valuable connections worldwide.

We specialise in investing in medical devices, hardware, and diagnostic technologies. As an angel syndicate, we provide critical funding and strategic support from the seed stage through to successful exits, empowering early-stage companies to achieve their full potential.

ABOUT OUR TEAM

Medtech By The Numbers

ACTIVE MEMBERS

START-UP COMPANIES

MILLION INVESTED

View Investment Portfolio

Joining the MedTech Syndicate has allowed me to leverage collective intelligence and resources, ultimately driving better investment outcomes. The camaraderie and support from fellow investors are invaluable

Ultan M
In the absence of a current specialist medtech VC, the presence of the Medtech Syndicate has supported innovation in the start up sector. The syndicate’s collective knowledge and strategic partnerships have made it easier to evaluate and close on more investments, accelerating my deal flow and increasing my overall portfolio. The collaborative environment fosters shared expertise, reduces due diligence work and enables me to make more informed investment decisions

Bernard C
Investing with the MedTech Syndicate has been a game-changer for me. The collaboration and shared expertise within the group have led to informed decision-making and a diversified portfolio that I couldn't have achieved alone.

John L
Investing with the MedTech Syndicate has been of real interest to me. The collaboration and shared expertise within the group have led to informed decision-making and a diversified portfolio that I couldn't have achieved alone. It allows us to use our own thoughts and collaborate with colleagues to see if something is worth investing in. It is definitely for a long term strategy and at the higher end of the risk scale. Having this as a smaller percentage of a persons investing strategy can lead to some interesting journeys and hopefully stellar returns. The thing that I enjoy most is having combined expertise in the room looking at the same pitch and different views emerging with some overall consensus.

Dermot T